Search Result

Isoforms Recommended:	K-Ras

Results for "

KRASG12D

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Drug Derivative (1) Histone Methyltransferase (1) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (1) Molecular Glues (1) PROTACs (2) Ras (21)
By Research Areas:	Cancer (22)
Click Chemistry:	Alkynes (7)

Inhibitors & Agonists

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157031S

KRASG12D-IN-2	Ras	Cancer
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157029S

KRASG12D-IN-1	Ras	Cancer
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-175144

KRASG12D-IN-6	Ligands for Target Protein for PROTAC Ras	Cancer
KRASG12D-IN-6 is a PROTAC target protein ligand that can be used to synthesize CH091138 (HY-175025). CH091138 is a potent and selective KRASG12D PROTAC degrader with anti-tumor activity .

HY-174243

KRASG12D-IN-5	Ras	Cancer
KRASG12D-IN-5 (Compound 241) is an orally active *KRAS(G12D)* inhibitor with an IC₅₀ of 11 nM. KRASG12D-IN-5 has potent anticancer activity with no significant cytotoxicity against BxPC-3 (WT), KRAS mutation AsPC-1 (G12D) and MIAPaCa-2 cells (G12C) with CC₅₀s of 10.37, 0.76 and 0.3 μM, respectively. KRASG12D-IN-5 can be used for cancer research, such as lung, pancreatic and colorectal cancer .

HY-163488

KRASG12D-IN-4	Ras	Cancer
KRASG12D-IN-4 (example 38) is a KRas ^G12D inhibitor with an IC₅₀ of 3.3 nM. KRASG12D-IN-4 inhibits proliferation of pancreatic cancer ASPC-1 cells with an IC₅₀ of 12 nM .

HY-162445

KRASG12D-IN-3	Ras	Cancer
KRASG12D-IN-3 (compound Z1084) is an orally active KRAS ^G12D inhibitor that inhibits the cell growth of AGS and AsPC-1 cells with IC₅₀ values of 0.38 nM and 1.23 nM, respectively .

HY-171255

KRAS G12D inhibitor 26	Ras	Cancer
KRAS G12D inhibitor 26 is a modulator of Kras, targeting Kras(G12D) with an IC₅₀ ≤ 100 nM .

HY-162445S

KRASG12D-IN-3-d3	Isotope-Labeled Compounds	Others
pan-KRAS-IN-5-d₃ is deuterated labeled pan-KRAS-IN-5.

HY-158007

(RS)-G12Di-1	Ras	Cancer
(RS)-G12Di-1 is a selective, covalent inhibitor of *K-Ras-G12D* .

HY-145962

MRTX-EX185	Ras	Cancer
MRTX-EX185 is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 also binds GDP-loaded HRAS . MRTX-EX185 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145962A

MRTX-EX185 formic	Ras	Cancer
MRTX-EX185 formic is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 formic also binds GDP-loaded HRAS . MRTX-EX185 (formic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-175025

CH091138	PROTACs Ras Apoptosis	Cancer
CH091138 is a potent and selective KRASG12D PROTAC degrader with DC₅₀s of 148.3 nM in HeLa cells and 469.8 nM in AsPC-1 cells. CH091138 selectively degrades exogenous and endogenous *KRASG12D* but not KRAS ^WT or other KRAS mutants (G12C/G12S/G12V), depending on the VHL-mediated ubiquitin-proteasome system. CH091138 exhibits potent anti-tumor activity and induces cancer cell apoptosis. CH091138 can be used for the study of pancreatic cancer and colon cancer. (Pink: KRASG12D ligand(HY-175144); Blue: VHL E3 ligase ligand (HY-138678); Black: Linker; VHL E3 ligase ligand + Linker (HY-136006B)) .

HY-176419

KRAS inhibitor-42	Ras	Cancer
KRAS inhibitor-42 (compound 8) is a potent USP7 inhibitor. KRAS inhibitor-42 has high affinity against GDP-bound KRASG12D with a K_i of 2.7 μM .

HY-170428

IPS-06061	Molecular Glues Ras	Cancer
IPS-06061 is an orally active molecule glue, that forms a ternary complex of CRBN-KRASG12D-IPS06061, and degrades KRAS G12D with a DC₅₀ <500 nM .

HY-159127

HRS-4642	Ras	Cancer
HRS-4642 is a selective *KRAS(G12D)* inhibitor (Kd=0.083 nM) with anti-cancer activity. HRS-4642 synergizes with Carfilzomib (HY-10455) and exhibits significant in vivo potency to reshape the tumor microenvironment into an immune-activating microenvironment.

HY-153663

TH-Z827	Ras	Cancer
TH-Z827 is a mutant selective *KRAS(G12D)* inhibitor with an IC₅₀ of 2.4 μM. TH-Z827 does not bind KRAS(WT) or KRAS(G12C). TH-Z827 blocked the KRAS(G12D)-CRAF interaction with an IC₅₀ value of 42 μM .

HY-173329

KRAS inhibitor-41	Ras	Cancer
KRAS inhibitor-41 is an inhibitor of KRAS with IC₅₀ values of <0.01 μM for KRAS G12D and KRAS G12V. KRAS inhibitor-41 inhibits RAS mutant cell lines, GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 can be used in cancer research .

HY-158008

(R)-G12Di-7	Ras	Cancer
(R)-G12Di-7 is a covalent ligand for *KRAS-G12D, which selectively labels K-Ras-G12D·GDP and K-Ras-G12D·GppNHp. (R)-G12Di-7 exhibits inhibitory activity against G12*D mutated cancer cells .

HY-126247

BI-2852	Ras	Cancer
BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.

HY-134813A

MRTX1133 formic	Ras	Cancer
MRTX1133 formic is a noncovalent, potent, and selective KRAS G12D inhibitor. MRTX1133 formic optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated K_D against KRAS G12D of 0.2 pM. MRTX1133 formic prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRASG12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. MRTX1133 formic shows efficacy in tumor models harboring KRAS G12D mutations .

HY-126247B

(R)-BI-2852	Drug Derivative Ras	Cancer
(R)-BI-2852 is the isomer of BI-2852 (HY-126247), and can be used as an experimental control. BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.

HY-173637

AZD0022	Ras	Cancer
AZD0022 is a selective and orally active KRAS ^G12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model .

HY-162749

G9D-4	PROTACs Histone Methyltransferase	Cancer
G9D-4 is a potent PROTAC degrader of G9a, with the DC₅₀ value of 0.1 μM in PANC-1 cells and do not directly perturb GLP protein, with the DC₅₀ of ＞10 μM. G9D-4 plays an important role in pancreatic cancer research (Pink: Ligand for target protein G9a/GLP Inhibitor (HY-15273); Black: Linker; Blue: Ligand for E3 ligase (HY-10984)) .

Species:	Human (3)
Tag:	His (3) Avi (3)
Source:	HEK293 (3)


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-157031S

KRASG12D-IN-2
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157029S

KRASG12D-IN-1
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-162445S

KRASG12D-IN-3-d3
pan-KRAS-IN-5-d₃ is deuterated labeled pan-KRAS-IN-5.

Cat. No.	Product Name		Classification

HY-157031S

KRASG12D-IN-2		Alkynes
KRASG12D-IN-2 (compound 28) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-157029S

KRASG12D-IN-1		Alkynes
KRASG12D-IN-1 (compound 22) is a KRAS ^G12D Inhibitor. KRASG12D-IN-1 has dose-dependent anti-tumor efficacy in the AsPC-1 xenograft mouse models with a tumor growth inhibition .

HY-145962A

MRTX-EX185 formic		Alkynes
MRTX-EX185 formic is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 formic also binds GDP-loaded HRAS . MRTX-EX185 (formic) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-163488

KRASG12D-IN-4		Alkynes
KRASG12D-IN-4 (example 38) is a KRas ^G12D inhibitor with an IC₅₀ of 3.3 nM. KRASG12D-IN-4 inhibits proliferation of pancreatic cancer ASPC-1 cells with an IC₅₀ of 12 nM .

HY-158007

(RS)-G12Di-1		Alkynes
(RS)-G12Di-1 is a selective, covalent inhibitor of *K-Ras-G12D* .

HY-145962

MRTX-EX185		Alkynes
MRTX-EX185 is a potent inhibitor of GDP-loaded KRAS and *KRAS(G12D), with an IC₅₀* of 90 nM for KRAS(G12D). MRTX-EX185 also binds GDP-loaded HRAS . MRTX-EX185 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-173637

AZD0022		Alkynes
AZD0022 is a selective and orally active KRAS ^G12D inhibitor. AZD0022 inhibits KRAS pathway suppression in the GP2D xenograft model .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: